GT Biopharma Inc. held its annual meeting of stockholders on July 24, 2025. During the meeting, four members were elected to the Board of Directors, including Michael Breen, Charles J. Casamento, Hilary Kramer, and David C. Mun-Gavin. The appointment of Weinberg & Company, P.A. as independent accountants for the year ending December 31, 2025, was ratified. The amendment to the GT Biopharma, Inc. 2022 Omnibus Incentive Plan, increasing the number of shares available for future awards by 583,334 shares of Common Stock, was approved. The issuance of 19.99% or more of the outstanding shares of Common Stock, as outlined in the Securities Purchase Agreement and the Common Shares Purchase Agreement, was also approved.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。